Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals

被引：99

作者：

Usmani, KA ^{[1
]}

Rose, RL ^{[1
]}

Hodgson, E ^{[1
]}

机构：

[1] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA

来源：

DRUG METABOLISM AND DISPOSITION | 2003年 / 31卷 / 04期

关键词：

D O I：

10.1124/dmd.31.4.384

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cytochrome P450 (P450) enzymes are major catalysts involved in the metabolism of xenobiotics and endogenous substrates such as testosterone (TST). Major TST metabolites formed by human liver microsomes include 6beta-hydroxytestosterone (6beta-OHTST), 2beta-hydroxytestosterone (2beta-OHTST), and 15beta-hydroxytestosterone (15beta-OHTST). A screen of 16 cDNA-expressed human P450 isoforms demonstrated that 94% of all TST metabolites are produced by members of the CYP3A subfamily with 6beta-OHTST accounting for 86% of all TST metabolites. Similar K-m values were observed for production of 6beta-, 2beta-, and 15beta-OHTST with human liver microsomes (HLM) and CYP3A4. However, V-max and CLint were significantly higher for 6beta-OHTST than 2beta-OHTST (similar to18-fold) and 15beta-OHTST (similar to40-fold). Preincubation of HLM with a variety of ligands, including chemicals used in military deployments, resulted in varying levels of inhibition or activation of TST metabolism. The greatest inhibition of TST metabolism in HLM was following preincubation with organophosphorus compounds, including chlorpyrifos, phorate, and fonofos, with up to 80% inhibition noticed for several metabolites including 6beta-OHTST. Preincubation of CYP3A4 with chlorpyrifos, but not chlorpyrifos-oxon, resulted in 98% inhibition of TST metabolism. Phorate and fonofos also inhibited the production of most primary metabolites of CYP3A4. Kinetic analysis indicated that chlorpyrifos was one of the most potent inhibitors of major TST metabolites followed by fonofos and phorate. Chlorpyrifos, fonofos, and phorate inhibited major TST metabolites noncompetitively and irreversibly. Conversely, preincubation of CYP3A4 with pyridostigmine bromide increased metabolite levels of 6beta-OHTST and 2beta-OHTST. Preincubation of human aromatase (CYP19) with the test chemicals had no effect on the production of the endogenous estrogen, 17beta-estradiol.

引用

页码：384 / 391

页数：8

共 34 条

[11] Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: Rapid reduction in the absence of substrate and variations among cytochrome P450 systems [J].

Guengerich, FP ;

Johnson, WW .

BIOCHEMISTRY, 1997, 36 (48) :14741-14750

[12] Self-reported exposure to neurotoxic chemical combinations in the Gulf War - A cross-sectional epidemiologic study [J].

Haley, RW ;

Kurt, TL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (03) :231-237

[13] CYP3A4 EXPRESSED BY INSECT CELLS INFECTED WITH A RECOMBINANT BACULOVIRUS CONTAINING BOTH CYP3A4 AND HUMAN NADPH-CYTOCHROME P450 REDUCTASE IS CATALYTICALLY SIMILAR TO HUMAN LIVER MICROSOMAL CYP3A4 [J].

LEE, CA ;

KADWELL, SH ;

KOST, TA ;

SERABJITSINGH, CJ .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1995, 319 (01) :157-167

[14] The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions [J].

Lehmann, JM ;

McKee, DD ;

Watson, MA ;

Willson, TM ;

Moore, JT ;

Kliewer, SA .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :1016-1023

[15] A yeast screen system for aromatase inhibitors and ligands for androgen receptor: Yeast cells transformed with aromatase and androgen receptor [J].

Mak, P ;

Dela Cruz, F ;

Chen, S .

ENVIRONMENTAL HEALTH PERSPECTIVES, 1999, 107 (11) :855-860

[16]

McCain WC, 1997, J TOXICOL ENV HEALTH, V50, P113, DOI 10.1080/009841097160528

[17]

Neal R.A., 1980, REV BIOCH TOXICOL, V2, P131, DOI [DOI 10.1016/B978-0-12-87702-6.50035-9, 10.1016/B978-0-12-87702-6.50035-9]

[18] P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature [J].

Nelson, DR ;

Koymans, L ;

Kamataki, T ;

Stegeman, JJ ;

Feyereisen, R ;

Waxman, DJ ;

Waterman, MR ;

Gotoh, O ;

Coon, MJ ;

Estabrook, RW ;

Gunsalus, IC ;

Nebert, DW .

PHARMACOGENETICS, 1996, 6 (01) :1-42

[19]

NIESCHLAG E, 1998, TESTOSTERONE ACTION

[20] Improved high-performance liquid chromatographic procedure for the separation and quantification of hydroxytestosterone metabolites [J].

Purdon, MP ;

LehmanMcKeeman, LD .

JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1997, 37 (02) :67-73

← 1 2 3 4 →